The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pazopanib versus paclitaxel in relapsed urothelial tumors: A randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive transitional cell carcinoma of the urothelium (PLUTO).
Robert J. Jones
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - AstraZeneca; GlaxoSmithKline
Other Remuneration - GlaxoSmithKline
John D. Chester
No relevant relationships to disclose
Judith Dixon-Hughes
No relevant relationships to disclose
Laura Alexander
No relevant relationships to disclose
Amit Bahl
No relevant relationships to disclose
Syed A. Hussain
Honoraria - Astellas Pharma; Bayer; Pierre Fabre Medicament
Research Funding - Bayer; Boehringer Ingelheim
Alison Birtle
No relevant relationships to disclose
Satinder Jagdev
No relevant relationships to disclose
Anna Morris
No relevant relationships to disclose
Jamie Stobo
No relevant relationships to disclose
Caroline A Bray
No relevant relationships to disclose
James Paul
No relevant relationships to disclose
Tom Powles
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline